Gema R.
- Country
- Spain
- Department
- Pediatric Oncology
Research Overview
- Phase 3 Non-Inferiority Trial of Vincristine, Actinomycin-D, and Doxorubicin Versus Vincristine, Carboplatin, and Etoposide in Stage IV Pediatric Renal Tumors
- Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations
- Phase I-II Evaluation of Sunitinib and Nivolumab with Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Data & Insights
Has run more than one trial at 77 of 205 partner sites.
Specializations
Sarcoma Research
This investigator specializes in the treatment of rhabdomyosarcoma, with particular emphasis on both frontline and relapsed cases in children and adults.
- Primary Disease Management
- Relapse Treatment Strategies
- Risk-Stratified Therapy
The investigator's work encompasses comprehensive treatment approaches for various risk categories, including very high-risk and high-risk disease presentations.
Therapeutic Innovation
The investigator focuses on developing novel combination therapies, including systemic treatment regimens and innovative drug combinations for improved patient outcomes.
- Combination Chemotherapy
- Maintenance Therapy
- Novel Drug Integration
Their research includes evaluation of various therapeutic combinations including irinotecan-based regimens and targeted agents.
Radiation Oncology
The investigator studies optimal radiotherapy approaches in sarcoma treatment, exploring timing and dosing strategies.
- Pre-operative Radiation
- Post-operative Radiation
- Dose Escalation Studies
Their work includes investigation of radiation therapy timing and its role in treating both primary tumors and metastatic sites.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.